

Date: 26/05/2021

**FREEDOM OF INFORMATION REQUEST - Ref: FOI/015690Neurology treatments (biologics)**

1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:

Aubagio (teriflunomide) - 31  
Avonex (interferon beta-1a) - 8  
Betaferon (interferon beta-1b) - 0  
Brabio (glatiramer acetate) - 0  
Copaxone (glatiramer acetate) - 7  
Extavia (beta interferon-1b) - 0  
Fampyra (fampridine) - 12  
Gilenya (fingolimod) - 24  
Lemtrada (alemtuzumab) - 0  
Mavenclad (cladribine) - 0  
Mayzent (siponimod) - 0  
Ocrevus (ocrelizumab) - 0  
Plegridy (peginterferon beta-1a) - 3  
Rebif (beta interferon-1a) - 7  
Tecfidera (dimethyl fumarate) - 68  
Tysabri (natalizumab) - 10  
Zeposia (ozanimod) - 0

Q2. How many patients have been treated with the following drugs in the past 4 months:

Ajoovy (fremanezumab) - any disease - 4  
Aimovig (erenumab) - any disease - 0  
Emgality (galcanezumab) - any disease - 0  
Botulinum Toxin (i.e. Botox, Dysport, Xeomin) - migraine ONLY - The Pharmacy database does not identify drugs against patient disease

Q3. How many patients have been treated in the past 4 months for the following conditions: - The Pharmacy database does not identify drugs against patient disease

Chronic migraine (15+ headache days per month)  
Episodic migraine (4-14 headache days per month)  
Primary progressive multiple sclerosis (PPMS)  
Secondary progressive multiple sclerosis (SPMS)